For the in-vitro-determination of the concentration of free Rituximab in EDTA plasma and serum
Rituximab is a chimeric monoclonal antibody against the B cell surface antigen CD20. It is used for the therapy of malign lymphomas and different autoimmune diseases (e. g. rheumatoid arthritis, granulomatosis with polyangiitis, immune thrombocytopenia, myasthenia gravis). As a drug rituximab is known as MabThera® or Rituxan®.
CD20 (also known as human B-lymphocyte-restricted differentiation antigen or Bp35) is a surface antigen on normal and malign pre-B-lymphocytes and mature B-lymphocytes, but it is not expressed on hematopoietic stem cells, pro-B-lymphocytes, plasma cells or cells of other tissues. CD20 supports the B-cell immune response, in particular against T-cell-independent antigens and maybe it works as a calcium channel.
By binding to CD20, rituximab improves for example the effect of natural killer (NK) cells which induce cell death in the B-lymphocytes marked with rituximab. Hereby the number of alive B-lymphocytes is clearly reduced, leading to an improvement in the symptoms. This is one of the targets of lymphoma therapy. In autoimmune disease therapy, the reduction of B-lymphocytes results in a reduction of autoantibodies, leading to a reduction of the symptoms.
Using this IDKmonitor® Rituximab drug level ELISA kit, you can determine the serum or plasma level of the therapeutic antibody rituximab. The results help the treating physician to monitor and optimise the therapy early on.
10 µl EDTA plasma or serum are diluted 1:2000 in dilution buffer for the test, 100 µl of this dilution are used for the ELISA.
IDKmonitor® Rituximab K 9661